Quantitative Prediction of OATP‐Mediated Drug‐Drug Interactions With Model‐Based Analysis of Endogenous Biomarker Kinetics

por Yoshida, Kenta, Guo, Cen, Sane, Rucha
Publicado 2018

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

por Sutaria, Dhruvitkumar S., Rasuo, Grozdana, Harris, Adam, Johnson, Ryan, Miles, Dale, Gallo, Jorge Daniel, Sane, Rucha
Publicado 2022

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model

por Jing, Jing, Chen, Yuan, Musib, Luna, Jin, Jin Y., Cheung, Kit Wun Kathy, Yoshida, Kenta, Sane, Rucha
Publicado 2022

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function

por Sane, Rucha, Malhi, Vikram, Sutaria, Dhruvitkumar S, Cho, Eunpi, Twomey, Patrick, Craggs, Christopher, Wang, Jianshuang, Harris, Adam, Musib, Luna
Publicado 2021

The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover study

por Müller, Fabian, Sand, Michael, Wunderlich, Glen, Link, Jasmin, Schultheis, Christian, Dansirikul, Chantaratsamon, Sane, Rucha, Laszlo, Roman, Steinacker, Jürgen M.
Publicado 2022

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

por Sutaria, Dhruvitkumar S., Agarwal, Priya, Huang, Kuan‐Chieh, Miles, Dale R., Rotmensch, Jacob, Hinton, Heather, Gallo, Jorge Daniel, Rasuo, Grozdana, Sane, Rucha S.
Publicado 2022

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study

por Kotani, Naoki, Wilkins, Justin J., Wade, Janet R., Dang, Steve, Sutaria, Dhruvitkumar S., Yoshida, Kenta, Sundrani, Sameer, Ding, Hao, Garcia, Josep, Hinton, Heather, Sane, Rucha, Chanu, Pascal
Publicado 2022